EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma

Mégane Jassin iD, Chloé Onkelinx, Valentina Bocuzzi, Bianca E Silva iD, Oswin Kwan iD, Alix Block, Sophie Dubois, Coline Daulne, Guillaume Marcion, Sandra Ormenese, Emmanuel Di Valentin iD, Frédéric Baron und 4 weitere

Cells · 08.12.2025 · 14 (24) · 1944

DOI: 10.3390/cells14241944 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cells, online erschienen am 08.12.2025. Verfasst von Mégane Jassin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematology, GIGA Institute, University of Liège, 4000 Liège, Belgium. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Single-Chain Antibodies, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de la Recherche Scientifique - FNRS, Télévie - FNRS, Stichting tegen Kanker.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is an incurable hematologic malignancy arising from clonal plasma cells, with poor long-term outcomes due to inevitable relapse after conventional therapies. Chimeric antigen receptor (CAR) T-cell immunotherapy targeting B-cell maturation antigen (BCMA) has shown remarkable efficacy in relapsed patients. Conventional CARs employ single-chain variable fragments (scFvs), whereas single-domain antibodies (sdAb or VHHs) offer advantages such as small size, high stability, and potentially reduced immunogenicity. We designed and evaluated a novel anti-BCMA nanoCAR-T based on the VHH Nb17, compared with the conventional scFv-based CAR-T CT103a. Nb17 demonstrated strong BCMA binding and was incorporated into a CAR construct. Both nanoCAR-T and CT103a were generated via lentiviral transduction of primary T cells. Their cytotoxicity, cytokine secretion, degranulation, memory phenotype, and gene expression were assessed in vitro, along with antitumor activity in vivo. Nb17-nanoCAR-T demonstrated specific cytotoxicity, cytokine release (IL-2, TFNa, IFNg), and CD107a degranulation comparable to CT103a. Transcriptomic analysis revealed overlapping pathways between both CARs. Upon rechallenge, both CARs showed enhanced proliferation compared with untransduced T cells. In vivo, Nb17-nanoCAR-T and CT103a eradicated tumors in NSG mice. These findings demonstrate Nb17-nanoCAR-T exhibits potent anti-myeloma efficacy comparable to scFv-based CAR-T, supporting its potential as a promising therapeutic alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaB-Cell Maturation AntigenSingle-Chain AntibodiesReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumansAnimalsMiceCell Line, TumorT-LymphocytesFemaleMice, Inbred NODXenograft Model Antitumor AssaysMice, SCID

Stichwörter der Autor:innen

BCMACAR-T cellsMMimmunotherapynanobody

Substanzen

B-Cell Maturation AntigenSingle-Chain AntibodiesReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Laboratory of Hematology, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • Department of Clinical Hematology, University Hospital Center (CHU) of Liège, 4000 Liège, Belgium.
  • Cell Imaging & Flow Cytometry Platform, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • Viral Vectors Platform, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • Walloon Excellence in Life Sciences and Biotechnology (WELBIO) Department, WEL Research Institute, 1300 Wavre, Belgium.

ORCID-Profile: Mégane Jassin, Bianca E Silva, Oswin Kwan, Emmanuel Di Valentin, Grégory Ehx

Förderung

  • Fonds de la Recherche Scientifique - FNRS
  • Télévie - FNRS
  • Stichting tegen Kanker
  • Fonds spéciaux (Université de Liège)
  • ERA-NET TRANSCAN-3
  • Foundation Against Cancer
  • Fonds National de la Recherche Scientifique
  • Télévie-FNRS

Zitieren

APA

Jassin, M., Onkelinx, C., Bocuzzi, V., E Silva, B., Kwan, O., Block, A., Dubois, S., Daulne, C., Marcion, G., Ormenese, S., Di Valentin, E., Baron, F., Grégoire, C., Ehx, G., Nguyen, T. T., & Caers, J. (2025). Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma. Cells, 14(24), 1944. https://doi.org/10.3390/cells14241944

Vancouver

Jassin M, Onkelinx C, Bocuzzi V, E Silva B, Kwan O, Block A, et al. Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma. Cells. 2025;14(24):1944. doi:10.3390/cells14241944

BibTeX
@article{Jassin2025,
  author = {Jassin, Mégane and Onkelinx, Chloé and Bocuzzi, Valentina and E Silva, Bianca and Kwan, Oswin and Block, Alix and Dubois, Sophie and Daulne, Coline and Marcion, Guillaume and Ormenese, Sandra and Di Valentin, Emmanuel and Baron, Frédéric and Grégoire, Céline and Ehx, Grégory and Nguyen, Tham Thi and Caers, Jo},
  title = {Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {24},
  pages = {1944},
  doi = {10.3390/cells14241944}
}
Kostenlos starten →